KDM5D and acute myeloid leukemia: Kdm5d-deficient HSPCs and low-KDM5D-expressing AML patients also shared the common leukemia-promoting HALLMARK_MYC_TARGETS_V2 pathway (human: NES = 1.88, P = 0.00; mouse: NES = 2.07, P = 0.00), which was consistent with those in both mouse and human mLOY AML (Figure 2H and Supplemental Figure 6C).